Ratings by Oppenheimer (Mazahir Alimohamed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/22/2026 | Tyra Biosciences | TYRA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Outperform (N/A) |
19.37 (31.73) |
63.81% | Details | |
| 7/9/2026 | Edgewise Therapeutics | EWTX | New Coverage | Outperform (N/A) |
46.30 (39.99) |
-13.63% | Details | |
| 6/22/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (Outperform) |
7.56 (2.85) |
-62.3% | Details | |
| 6/17/2026 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
28.21 (20.87) |
-26.02% | Details | |
| 6/10/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Outperform (N/A) |
1.67 (1.63) |
-2.4% | Details | |
| 5/20/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Outperform (N/A) |
60.97 (72.08) |
18.22% | Details | |
| 4/24/2026 | Inflarx NV | IFRX | New Coverage | Outperform (N/A) |
1.56 (1.53) |
-1.92% | Details | |
| 4/24/2026 | Savara | SVRA | New Coverage | Outperform (N/A) |
4.94 (4.54) |
-8.1% | Details | |
| 4/24/2026 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
4.07 (4.13) |
1.47% | Details |
